BloodScan is proud to have been recognized as a Top 6 finalist in the Disruptive Technology Award at the ADLM Annual Meeting, highlighting our innovation in next-generation cancer diagnostic technologies.

As part of this recognition, BloodScan was invited to present and showcase its technology at the ADLM exhibition, providing an international platform to demonstrate our advancements in circulating tumor cell (CTC) enrichment and liquid biopsy solutions.

This milestone reflects the strong potential of BloodScan’s proprietary Labyrinth One platform, which enables high-efficiency, label-free CTC isolation while preserving cell integrity for downstream analysis. The recognition from ADLM underscores our commitment to advancing precision oncology and transforming early cancer detection.

We sincerely appreciate ADLM for the opportunity and recognition, and we look forward to continuing our mission of bringing innovative liquid biopsy technologies to global research and clinical applications.